China is rapidly transforming into a global hub for pharmaceutical innovation. The number of novel drugs in China for cancer, weight-loss and others entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the US’s count of about 1,440
As featured in a recent Bloomberg article, Chinese drugmakers are not just catching up, they're redefining global benchmarks for speed, scale, and scientific ambition.
According to Andy Liu, China Head at Novotech, the shift is structural and strategic:
“China speed” is more than a catchphrase, it’s a real competitive advantage.
He adds,“They can leapfrog competitors in other countries,”citing streamlined approvals, faster trial startups, and a cultural focus on execution.
What This Means for Global Sponsors
For biotech companies looking to accelerate development and expand globally, China’s clinical research ecosystem now offers:
- Unmatched trial efficiency – Sponsors benefit from rapid patient recruitment, centralized healthcare infrastructure, and shortened timelines.
- Innovation-driven pipelines – Chinese companies are delivering first-in-class candidates with real global potential, many of which are now licensed to Western pharma.
- Regulatory momentum – Updated frameworks from the NMPA have increased transparency and alignment with international standards, boosting global confidence in local data.
Novotech’s Role in Accelerating Access
As the leading global CRO, Novotech provides the benefits of a multinational partner, with the regional expertise needed to help sponsors leverage China’s unique advantages, without compromising global quality or timelines.
With operations across mainland China and throughout the region, Novotech supports biotech and pharma innovators from first-in-human studies to late-phase trials, offering scalable solutions built for speed and scientific rigor.
Read the full article on Bloomberg:
China Drugmakers Are Catching Up to Big Pharma With New Innovation